Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
- 1 April 1984
- journal article
- Published by Springer Nature in Annals of Hematology
- Vol. 48 (4) , 239-242
- https://doi.org/10.1007/bf00319816
Abstract
Ten AML- and two MDS-patients in whom conventional chemotherapy was contraindicated or ineffective were treated with low dose ARA-C, 10 mg/m2 per 12hs.c. for 2–4 weeks. Seven patients obtained a complete and two a partial remission. Our findings suggest that low dose ARA-C may act both by induction of differentiation and/or inhibition of proliferation.Keywords
This publication has 7 references indexed in Scilit:
- Does treatment with ARA-C in low dosage cause differentiation of leukemic cells?Blood, 1983
- Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: Results of a pilot study in four patientsLeukemia Research, 1983
- Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?British Journal of Haematology, 1982
- Treatment of Early Acute Nonlymphatic Leukemia with Low Dose Cytosine ArabinosidePublished by Springer Nature ,1981
- DIFFERENTIATION OF MYELOID LEUKAEMIC CELLS: NEW POSSIBILITIES FOR THERAPYBritish Journal of Haematology, 1979
- THE DIFFERENTIATION OF MYELOID LEUKAEMIA CELLS: NEW POSSIBILITIES FOR THERAPYBritish Journal of Haematology, 1978
- Different Blocks in the Differentiation of Myeloid Leukemic CellsProceedings of the National Academy of Sciences, 1974